Mechanism of action<unk>  is a tyrosine kinase inhibitor that selectively and potently inhibits anaplastic lymphoma kinase (ALK). In normal physiology, ALK functions as a key step in the development and function of nervous system tissue. However, chromosomal translocation and fusion give rise to an oncogenic form of ALK that has been implicated in progression of NSCLC.<unk>  thus acts to inhibit this mutated enzyme and stop cell proliferation, ultimately halting cancer progression. Because<unk>  is considered a targeted cancer therapy, an FDA-approved test is required to determine which patients are candidates for<unk> . This test, developed by Roche, is the VENTANA ALK (D5F3) CDx Assay and is used to identify ALK-positive NSCLC patients who would benefit from<unk>  treatment.
Ceritinib
Axitinib
Abrocitinib
Sunitinib
Baricitinib
Erdafitinib
Upadacitinib
Dacomitinib